Skip to main content
letter
. 2022 Jun 23;107(10):2485–2491. doi: 10.3324/haematol.2022.280660

Figure 3.

Figure 3.

Response rates in patients with relapsed/refractory multiple myeloma according to treatment and 1q21+ status. (A) Overall response and very good partial response or better in each treatment arm of ICARIA-MM, and (B) overall response, very good partial response or better, and minimal residual disease negativity rate in each treatment arm of IKEMA, according to 1q21+ status. Minimal residual disease negativity was assessed by next-generation sequencing at 10-5 sensitivity. 1q21+ definition: ≥3 copies, 30% cutoff, with or without high-risk chromosomal abnormalities. Isolated 1q21+ definition: ≥3 copies, 30% cutoff, without high-risk chromosomal abnormalities. Gain(1q21) definition: 3 copies, 30% cutoff, with or without high-risk chromosomal abnormalities. Amp(1q21) definition: ≥4 copies, 30% cutoff, with or without high-risk chromosomal abnormalities. Amp: amplification; d: dexamethasone; Isa: isatuximab; K: carfilzomib; MRD: minimal residual disease; P: pomalidomide; VGPR: very good partial response.